Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Quantitative magnetic resonance imaging biomarkers of disease progression in multiple sclerosis
EF 2020-21
Résumé
Canada has one of the highest rates of multiple sclerosis (MS) in the world. More than half of the MS population will develop a progressive form of the disease (gradual accumulation of disability independent of MS attacks). At this time, however, there is only limited treatment available for progressive MS in Canada. This lack of effective treatment is largely due to an inadequate understanding of underlying biological mechanisms of the disease that is responsible for MS progression. Furthermore, clinical measures of progression change slowly and require a large number of study participants, who are monitored over a long period to detect treatment effects. Effective markers of progression thus represent an urgent and unmet need in the development of progressive MS treatment. We aim to use non-invasive, quantitative imaging techniques to study brain and spinal cord pathology (biology resulting in disease) and its relationship to global disability (e.g. ambulation, dexterity, visual acuity and cognition) annually over 4 years. We will use the data collected from the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) - the largest Canadian study bringing together several study fields across 5 institutions to better understand MS progression over time. CanProCo is led by my supervisor, Dr. Jiwon Oh. We expect to establish biologically relevant imaging markers for MS progression that can 1) be used as outcome measures in shorter and less costly drug therapy trials in the future, which will accelerate the development of effective therapies, 2) monitor disease activity or tissue repair over time, and 3) evaluate the effectiveness of treatment or predict therapeutic outcomes to enable optimal clinical management. Our findings would be important for scientists, doctors, policymakers, people with MS and their caregivers by providing informational evidence to improve health policies and quality of life for people affected by MS.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
436842
Name
Lee Eun Young
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Quantitative magnetic resonance imaging biomarkers of disease progression in multiple sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Brain; Central Nervous System; Disease Progression; Magnetic Resonance Imaging; Multiple Sclerosis; Myelin; Neuroimaging; Quantitative Imaging; Spinal Cord
Abstract
Canada has one of the highest rates of multiple sclerosis (MS) in the world. More than half of the MS population will develop a progressive form of the disease (gradual accumulation of disability independent of MS attacks). At this time, however, there is only limited treatment available for progressive MS in Canada. This lack of effective treatment is largely due to an inadequate understanding of underlying biological mechanisms of the disease that is responsible for MS progression. Furthermore, clinical measures of progression change slowly and require a large number of study participants, who are monitored over a long period to detect treatment effects. Effective markers of progression thus represent an urgent and unmet need in the development of progressive MS treatment. We aim to use non-invasive, quantitative imaging techniques to study brain and spinal cord pathology (biology resulting in disease) and its relationship to global disability (e.g. ambulation, dexterity, visual acuity and cognition) annually over 4 years. We will use the data collected from the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) - the largest Canadian study bringing together several study fields across 5 institutions to better understand MS progression over time. CanProCo is led by my supervisor, Dr. Jiwon Oh. We expect to establish biologically relevant imaging markers for MS progression that can 1) be used as outcome measures in shorter and less costly drug therapy trials in the future, which will accelerate the development of effective therapies, 2) monitor disease activity or tissue repair over time, and 3) evaluate the effectiveness of treatment or predict therapeutic outcomes to enable optimal clinical management. Our findings would be important for scientists, doctors, policymakers, people with MS and their caregivers by providing informational evidence to improve health policies and quality of life for people affected by MS.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lee, Eun Young
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~